Neuroprotective effect of gold nanoparticles composites in Parkinson's disease model

Hu, Kaikai; Chen, Xiaohui; Chen, Wuya; Zhang, Lingkun; Li, Jian; Ye, Jialin; Zhang, Yuxiao; Zhang, Li; Li, Chu-Hua; Yin, Liang; Guan, Yan‐Qing

doi:10.1016/j.nano.2018.01.020

Cited by 92 publications

(43 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The CTS@GNP-pDNA-NGF systems that resulted were transfected into cells by NGF receptor-mediated endocytosis, in order to suppress the expression of α-syn and inhibit the apoptosis of PC12 cells and substantia nigra striatum dopaminergic neurons. The data confirmed that CTS@GNP-pDNA-NGF presented notable therapeutic properties in both in vitro and in vivo PD models [125].…”

Section: Current Research Advances In Nanoparticle-based Treatmentsupporting

confidence: 67%

Nanomaterials for Drug Delivery to the Central Nervous System

et al. 2019

View full text Add to dashboard Cite

The intricate microstructure of the blood-brain barrier (BBB) is responsible for the accurate intrinsic regulation of the central nervous system (CNS), in terms of neuronal pathophysiological phenomena. Any disruption to the BBB can be associated with genetic defects triggering or with local antigenic invasion (either neurotoxic blood-derived metabolites and residues or microbial pathogens). Such events can be further related to systemic inflammatory or immune disorders, which can subsequently initiate several neurodegenerative pathways. Any degenerative process related to the CNS results in progressive and yet incurable impairment of neuronal cells. Since these particular neurons are mostly scanty or incapable of self-repair and regeneration processes, there is tremendous worldwide interest in novel therapeutic strategies for such specific conditions. Alzheimer’s and Parkinson’s diseases (AD and PD, respectively) are conditions found worldwide, being considered the most rampant degenerative pathologies related to CNS. The current therapy of these conditions, including both clinical and experimental approaches, mainly enables symptom management and subsidiary neuronal protection and even less disease regression. Still, a thorough understanding of the BBB pathophysiology and an accurate molecular and sub-molecular management of AD and PD will provide beneficial support for more specific and selective therapy. Since nanotechnology-derived materials and devices proved attractive and efficient platforms for modern biomedicine (including detection, imaging, diagnosis, medication, restoration and regeneration), a particular approach for AD and PD management relies on nanoparticle-based therapy. In this paper we will discuss relevant aspects related to the BBB and its impact on drug-based treatment and emphasize that nanoparticles are suitable and versatile candidates for the development of novel and performance-enhanced nanopharmaceuticals for neurodegenerative conditions therapy.

show abstract

Section: Current Research Advances In Nanoparticle-based Treatmentsupporting

confidence: 67%

Nanomaterials for Drug Delivery to the Central Nervous System

et al. 2019

View full text Add to dashboard Cite

show abstract

“…90 There are also many reports indicating the advantages of using NPs in PD therapy. 10 Hu et al 91 analyzed Au NPs loaded with plasmid DNA and obtained through the combination of electrostatic adsorption and photochemical immobilization methods with regard to their therapeutic effects in PD models. 91 The authors observed that these systems could successfully cross the BBB and inhibit the apoptosis of PC12 cells and dopaminergic neurons in PD mice brain.…”

Section: Neurodegenerative Diseasesmentioning

confidence: 99%

“…10 Hu et al 91 analyzed Au NPs loaded with plasmid DNA and obtained through the combination of electrostatic adsorption and photochemical immobilization methods with regard to their therapeutic effects in PD models. 91 The authors observed that these systems could successfully cross the BBB and inhibit the apoptosis of PC12 cells and dopaminergic neurons in PD mice brain. In a study conducted by Cao et al, 92 rat models of PD were separately given chitosan-coated levodopa liposomes/benserazide and levodopa/benserazide.…”

Section: Neurodegenerative Diseasesmentioning

confidence: 99%

Evaluation of the potential of nanoparticles containing active substances in selected chronic diseases

Sarecka-Hujar¹,

Banyś²,

Ostróżka-Cieślik³

et al. 2020

Adv Clin Exp Med

View full text Add to dashboard Cite

show abstract

“…Alternatively, suppression of α-syn overexpression has been demonstrated using gold NPs which could load plasmid DNA, cross the blood–brain barrier and target specific cells. For example, the group of Y. Guan achieved successful results in carrying pDNA into the neurons, and thus inhibiting dopaminergic neuron apoptosis (Hu et al, 2018). These approaches have the potential to suppress α-syn expression, providing a highly efficient treatment for PD.…”

Section: New Technologies For the Diagnosis Clinical Assessment And mentioning

confidence: 99%

Advances in Parkinson’s Disease: 200 Years Later

et al. 2018

View full text Add to dashboard Cite

When James Parkinson described the classical symptoms of the disease he could hardly foresee the evolution of our understanding over the next two hundred years. Nowadays, Parkinson’s disease is considered a complex multifactorial disease in which genetic factors, either causative or susceptibility variants, unknown environmental cues, and the potential interaction of both could ultimately trigger the pathology. Noteworthy advances have been made in different fields from the clinical phenotype to the decoding of some potential neuropathological features, among which are the fields of genetics, drug discovery or biomaterials for drug delivery, which, though recent in origin, have evolved swiftly to become the basis of research into the disease today. In this review, we highlight some of the key advances in the field over the past two centuries and discuss the current challenges focusing on exciting new research developments likely to come in the next few years. Also, the importance of pre-motor symptoms and early diagnosis in the search for more effective therapeutic options is discussed.

show abstract

Neuroprotective effect of gold nanoparticles composites in Parkinson's disease model

Cited by 92 publications

References 60 publications

Nanomaterials for Drug Delivery to the Central Nervous System

Nanomaterials for Drug Delivery to the Central Nervous System

Evaluation of the potential of nanoparticles containing active substances in selected chronic diseases

Advances in Parkinson’s Disease: 200 Years Later

Contact Info

Product

Resources

About